PL1802334T3 - Sposób leczenia wewnątrzgałkowych chorób neowaskularnych - Google Patents

Sposób leczenia wewnątrzgałkowych chorób neowaskularnych

Info

Publication number
PL1802334T3
PL1802334T3 PL05816281T PL05816281T PL1802334T3 PL 1802334 T3 PL1802334 T3 PL 1802334T3 PL 05816281 T PL05816281 T PL 05816281T PL 05816281 T PL05816281 T PL 05816281T PL 1802334 T3 PL1802334 T3 PL 1802334T3
Authority
PL
Poland
Prior art keywords
neovascular diseases
intraocular neovascular
treating intraocular
treating
diseases
Prior art date
Application number
PL05816281T
Other languages
English (en)
Inventor
Naveed Shams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1802334(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1802334T3 publication Critical patent/PL1802334T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05816281T 2004-10-21 2005-10-21 Sposób leczenia wewnątrzgałkowych chorób neowaskularnych PL1802334T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62120904P 2004-10-21 2004-10-21
PCT/US2005/038006 WO2006047325A1 (en) 2004-10-21 2005-10-21 Method for treating intraocular neovascular diseases
EP05816281A EP1802334B1 (en) 2004-10-21 2005-10-21 Method for treating intraocular neovascular diseases

Publications (1)

Publication Number Publication Date
PL1802334T3 true PL1802334T3 (pl) 2013-01-31

Family

ID=35708845

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05816281T PL1802334T3 (pl) 2004-10-21 2005-10-21 Sposób leczenia wewnątrzgałkowych chorób neowaskularnych

Country Status (13)

Country Link
US (2) US20070190058A1 (pl)
EP (4) EP2319492A3 (pl)
AU (1) AU2005299701B2 (pl)
CA (1) CA2584305A1 (pl)
DK (1) DK1802334T3 (pl)
ES (1) ES2390676T3 (pl)
HR (1) HRP20120902T1 (pl)
NZ (3) NZ596663A (pl)
PL (1) PL1802334T3 (pl)
PT (1) PT1802334E (pl)
RS (1) RS52539B (pl)
SI (1) SI1802334T1 (pl)
WO (1) WO2006047325A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
EA016227B1 (ru) * 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
AU2009295960A1 (en) 2008-09-29 2010-04-01 Cardiaq Valve Technologies, Inc. Heart valve
EP2341871B1 (en) 2008-10-01 2017-03-22 Edwards Lifesciences CardiAQ LLC Delivery system for vascular implant
EP4119098A1 (en) 2009-04-15 2023-01-18 Edwards Lifesciences CardiAQ LLC Vascular implant and delivery system
AR078060A1 (es) * 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
WO2011017313A1 (en) * 2009-08-04 2011-02-10 Copernicus Therapeutics Inc. Method of administering non-viral nucleic acid vectors to the eye
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9682197B2 (en) 2011-08-23 2017-06-20 Itech Jv Development Company, Llc Systems and methods for performing an injection
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
PL3777834T3 (pl) 2012-06-01 2022-05-30 Novartis Ag Strzykawka
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RU2630202C1 (ru) * 2016-09-30 2017-09-05 Публичное акционерное общество "Газпром" Способ извлечения фракции С2+ из сырого газа и установка для его осуществления
FI3600456T3 (fi) 2017-03-27 2023-10-26 Regeneron Pharma Sterilointimenetelmä
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
TW202116802A (zh) 2019-09-13 2021-05-01 瑞士商諾華公司 治療眼部疾病之方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
IT8121814U1 (it) 1981-05-19 1982-11-19 Nordica Spa Struttura di scarpetta interna particolarmente per scarponi da sci
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223407A (en) 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP2005511576A (ja) * 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
US20050043220A1 (en) * 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration

Also Published As

Publication number Publication date
CA2584305A1 (en) 2006-05-04
EP2324848A2 (en) 2011-05-25
EP2311433A3 (en) 2011-08-10
AU2005299701B2 (en) 2011-11-17
SI1802334T1 (sl) 2012-12-31
PT1802334E (pt) 2012-11-28
ES2390676T3 (es) 2012-11-15
EP2319492A3 (en) 2011-08-10
NZ598502A (en) 2013-07-26
EP1802334B1 (en) 2012-08-29
AU2005299701A1 (en) 2006-05-04
AU2005299701A2 (en) 2006-05-04
US20070190058A1 (en) 2007-08-16
EP1802334A1 (en) 2007-07-04
WO2006047325A1 (en) 2006-05-04
NZ596663A (en) 2013-07-26
EP2311433A2 (en) 2011-04-20
NZ590132A (en) 2012-03-30
RS52539B (sr) 2013-04-30
HRP20120902T1 (hr) 2012-12-31
DK1802334T3 (da) 2012-10-15
EP2324848A3 (en) 2011-09-14
US20140086934A1 (en) 2014-03-27
HK1102106A1 (en) 2007-11-09
EP2319492A2 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
PT1802334E (pt) Método para tratamento de doenças neovasculares intraoculares
ZA200508427B (en) Methods for treating interleuking-6 related diseases
EP1715799A4 (en) METHOD FOR TREATING GLAUCOMA
PL1655036T3 (pl) Sposób leczenia chorób onkologicznych
IL241756A0 (en) Preparations and methods for the treatment of diseases of safty tumors
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL180645A0 (en) Methods for treating hepatitis c
IL179139A0 (en) Method for treating multiple sclerosis
EP1742641A4 (en) METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF RETINA DISEASES
IL182837A0 (en) Methods, assays and compositions for treating retinol-related diseases
IL175818A0 (en) Method for treating adamts-5- associated disease
IL179325A0 (en) Method for treating lupus
AU2003303198A8 (en) Method for treating amyloid disease
ZA200705297B (en) Methods and compositions for treating amyloid related diseases
IL183059A0 (en) Cancer treatment method
EP1755394A4 (en) METHOD OF TREATING CANCER
GB0403600D0 (en) Methods and reagents for treating disease
IL179323A0 (en) Cancer treatment method
EP1809276A4 (en) PROCESSING PROCESS
IL179359A0 (en) Cancer treatment method
ZA200701235B (en) Methods for treating hepatitis C
EP1802617A4 (en) CANCER TREATMENT METHOD
EP1845998A4 (en) METHOD FOR TREATING NEUROLOGICAL DISEASES
ZA200609978B (en) Method for treating lupus
AU2003300471A8 (en) Methods for treating ocular diseases